03 January 2023: Original Paper
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and Relapse Settings: A Retrospective Study in China
Jing Liu 1BCDEF* , Haitao Wang 1BCDF* , Xiaohong Li 1B , Yamei Wu 1B , Yuanyuan Ma 1B , Zhenyang Gu 1B , Fei Li 1B , Meng Li 1BD , Jiayuan Guo 2B , Yu Zhao 1B , Quanshun Wang 1B , Jian Bo 1B , Wenrong Huang 1B , Liping Dou 1BD , Yuanbo Liu 3AEF , Daihong Liu 1BD , Xiaoxiong Wu 1ADF* , Chunji Gao 1ADEFG*DOI: 10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
Table 2 ASCT as consolidation treatment for patients newly diagnosed with PCNSL.
| Sex/age | Patient | ECOG | Conditioning regimen | Pre-ASCT | Post-ASCT | Timing of WBRT | N/P engraftment time (days) | Toxicity | ||
|---|---|---|---|---|---|---|---|---|---|---|
| M/45 | 1 | 2 | BEAM | CR | CR | After ASCT | 9/9 | Haematologic toxicities, gastrointestinal toxicities | ||
| M/28 | 2 | 2 | BEAM | CR | CR | – | 11/22 | Haematologic toxicities, fever | ||
| M/61 | 3 | 2 | TBC-like | CR | CR | – | 9/21 | Haematologic toxicities, fever, hepatotoxicity, gastrointestinal toxicities, creatinine increased | ||
| F/48 | 4 | 2 | TBC-like | CR | CR | – | 9/15 | Haematologic toxicities, fever, gastrointestinal toxicities, mucositis | ||
| M/51 | 5 | 3 | TBC-like | CR | CR | – | 8/15 | Haematologic toxicities, hepatotoxicity, fever | ||
| M/33 | 6 | 2 | Modified TBC | CR | CR | – | 10/15 | Haematologic toxicities, gastrointestinal toxicities, infection, mucositis, rash | ||
| F/21 | 7 | 0 | Modified TBC | CR | CR | – | 12/14 | Haematologic toxicities, gastrointestinal toxicities, infection | ||
| M/62 | 8 | 1 | Modified TBC | CR | CR | – | 16/25 | Haematologic toxicities | ||
| F/32 | 9 | 2 | Modified TBC | CR | CR | Before ASCT | 15/25 | Haematologic toxicities, pneumonia | ||
| M/26 | 10 | 0 | Modified TBC | CR | CR | – | 11/31 | Haematologic toxicities, gastrointestinal toxicities | ||
| M/45 | 1 | Epilepsy | Brain | WBRT | CR | 32.0 | 41.2 | DOD | ||
| M/28 | 2 | – | – | – | – | 42.4 | 42.4 | A Wo D | ||
| M/61 | 3 | – | – | – | – | 6.2 | 6.2 | A Wo D | ||
| F/48 | 4 | – | – | – | – | 11.5 | 11.5 | A Wo D | ||
| M/51 | 5 | – | – | – | – | 14.3 | 14.3 | A Wo D | ||
| M/33 | 6 | – | – | – | – | 3.3 | 3.3 | A Wo D | ||
| F/21 | 7 | – | – | – | – | 12.2 | 12.2 | A Wo D | ||
| M/62 | 8 | – | – | – | – | 29.0 | 29.0 | A Wo D | ||
| F/32 | 9 | – | – | – | – | 27.9 | 27.9 | A Wo D | ||
| M/26 | 10 | – | – | – | – | 2.5 | 2.5 | A Wo D | ||
| N/P – neutrophil/platelet; TBC – thiotepa + busulfan + cyclophosphamide; BEAM – carmustine + etoposide + cytarabine + melphalan; Modified TBC – TBC + cladribine + etoposide + cytarabine; CR – complete remission; Cru – unconfirmed CR; HDC – high-dose chemotherapy; PFS – progression-free survival; OS – overall survival; A Wo D – alive without disease; DOD – dead of disease. OS1 and PFS1 were measured from the day of transplantation. | ||||||||||